Cipla has launched a generic drug Sofosbuvir for treating chronic Hepatitis C under the brand name ‘Hepcvir’ in India. The availability of the product in other markets is subject to approvals from regulatory authorities in respective countries.
Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C, which reduce the need for injectables.
Earlier, pharmaceutical firm Dr. Reddyâ€™s entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences Hepatitis C drug under the brand â€˜Resofâ€™ in India.
In India, around 12-18 million patients are estimated to be infected with Hepatitis C, which is several fold greater fold greater than those with HIV/AIDS.